Results 91 to 100 of about 3,811,568 (245)

Analysis of Notch1 and Notch3 Signaling Pathway Components in Benign Prostatic Hyperplasia and Prostate Cancer Patients

Journal of Clinical Laboratory Analysis, EarlyView.
This study evaluates the association between Notch1 and Notch3 genetic variations and serum protein levels in patients with benign prostatic hyperplasia and prostate cancer. While genetic variations showed no significant link to disease risk, serum protein levels were significantly lower in prostate cancer and metastatic groups compared to healthy ...
Emine Yagci, Cansu Ozbayer, Ata Ozen, Gamze Zengin, Hulyam Kurt   +4 more
wiley   +1 more source

Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer

IJU Case Reports, 2019
Introduction Abiraterone acetate in combination with prednisone is now widely used for the treatment of castration‐resistant prostate cancer. Case presentation A 62‐year‐old patient with a bone metastatic castration‐resistant prostate cancer was started ...
Yoshinori Yanai, Takeo Kosaka, Hiroshi Hongo, Mototsugu Oya   +3 more
doaj   +1 more source

Bipolar Androgen Therapy as a Potential Mechanistic Bridge to Enhance PARP Inhibitor Efficacy in Prostate Cancer

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Prostate cancer remains a leading cause of cancer‐related mortality, largely driven by progression to metastatic castration‐resistant prostate cancer (mCRPC). Although poly(ADP‐ribose) polymerase inhibitors (PARPis) have improved outcomes in patients with homologous recombination repair (HRR) alterations, particularly in BRCA2‐mutated disease,
Jhen‐Hao Jhan, Jiun‐Hung Geng, Hung‐Lung Ke, Shu‐Pin Huang, Li Jia   +4 more
wiley   +1 more source

Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions

, 2016
Orazio Caffo, Francesca Maines, Mimma Rizzo, Stefania Kinspergher, Antonello Veccia Medical Oncology Department, Santa Chiara Hospital, Trento, Italy Abstract: The treatment of elderly patients with cancer is usually viewed by clinicians as a challenge,
Caffo O, Veccia A, Kinspergher S, Rizzo M, Maines F   +4 more
core  

Data‐Independent Acquisition Mass Spectrometry in Tumor Classification and Cancer Biomarker Research

Mass Spectrometry Reviews, EarlyView.
Abstract Cancer treatment is far from optimal also because current classification systems do not reflect the complex molecular status of the tumor and its phenotype in sufficient detail. To construct molecular tumor classifiers, omics tools provide complex molecular data reflecting many aspects from genotype to phenotype.
Jan Simonik, Petr Lapcik, Pavla Bouchalova, Pavel Bouchal   +3 more
wiley   +1 more source

Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer.

PURPOSE: Although numerous biology-driven subtypes have been described previously in metastatic castration-resistant prostate cancer (mCRPC), unsupervised molecular subtyping based on gene expression has been less studied, especially using large cohorts.
Quigley, DA, Sjöström, M, Feng, E, Lundberg, A, Rydzewski, NR, Helzer, KT, Aggarwal, R, Zhang, M, Zhao, SG, Bootsma, M, Small, EJ, Lang, JM   +11 more
core   +1 more source

Insulin‐Like Growth Factor Axis and Survival in Metastatic Hormone‐Sensitive Prostate Cancer: Post‐Hoc Analysis From the ENZAMET Phase 3 Trial

The Prostate, EarlyView.
ABSTRACT Background A higher ratio of IGF‐1:IGF binding protein 1 (IGFBP1) was associated with improved prognosis in the CHAARTED trial of docetaxel in participants with metastatic hormone‐sensitive prostate cancer (mHSPC). The ENZAMET trial demonstrated the survival benefit of adding enzalutamide to androgen deprivation therapy (ADT) in mHSPC, and ...
Michael A. Cilento, Hui‐Ming Lin, Nicole Yeung, Rachel M.N. Kim, Neil Portman, Martin R. Stockler, Andrew J. Martin, Vinod Subhash, Sonia Yip, Lisa M. Butler, Ian C. Marschner, Peter J. Meikle, Arun A. Azad, Ian D. Davis, Lisa G. Horvath, Christopher J. Sweeney   +15 more
wiley   +1 more source

Survival Outcomes by Frailty and Comorbidities in Veterans Treated With Abiraterone and Enzalutamide for Metastatic Castration‐Resistant Prostate Cancer

The Prostate, EarlyView.
ABSTRACT Background Androgen receptor pathway inhibitors (ARPIs) such as abiraterone and enzalutamide are common therapies in the management of metastatic castration‐resistant prostate cancer (mCRPC). However, the comparative effectiveness of these oral ARPIs in frail and comorbid patient populations remains uncertain.
Meghana Yellanki, Jennifer La, Danne C. Elbers, Nhan V. Do, Channing J. Paller, Nathanael R. Fillmore, Martin W. Schoen   +6 more
wiley   +1 more source

MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer

Nature Communications, 2020
MUC1-C is overexpressed in castration-resistant prostate cancer and neuroendocrine prostate cancer. Here, the authors show that MUC1-C drives lineage plasticity through MYC and BRN2, inducing neuroendocrine features and stemness in prostate cancer.
Yota Yasumizu, Hasan Rajabi, Caining Jin, Tsuyoshi Hata, Sean Pitroda, Mark D. Long, Masayuki Hagiwara, Wei Li, Qiang Hu, Song Liu, Nami Yamashita, Atsushi Fushimi, Ling Kui, Mehmet Samur, Masaaki Yamamoto, Yan Zhang, Ning Zhang, Deli Hong, Takahiro Maeda, Takeo Kosaka, Kwok K. Wong, Mototsugu Oya, Donald Kufe   +22 more
doaj   +1 more source

In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumours

, 2009
Purpose: Progression to the castration-resistant state is the incurable and lethal end stage of prostate cancer, and there is strong evidence that androgen receptor (AR) still plays a central role in this process.
Snoek, Robert, Gleave, Martin, Fazli, Ladan, Wong, Charmaine, Chan Wong, Erica, Margiotti, Katia, Rennie, Paul, Nelson, Colleen, Cheng, Helen, Wafa, Latif   +9 more
core   +1 more source